Unleash the potential of genome engineering to create tomorrow’s cure for today’s incurable diseases
- Deploy advanced engineering of the human genome
- Accelerate the development of new life saving therapies
Welcome to Genome Engineering at R&D Systems!
If you’re familiar with B-MoGen as experts in gene engineering, you’ll find the same cutting-edge technologies and services on these pages.
We’d love to keep you up to date as we develop even more capabilities. If you’d like to receive these updates, please click below and sign up.
Send Me Updates
B-MoGen is now R&D Systems. Genome Engineering Services from the Same Team with the Same Expertise.
TcBuster™ is a next-generation non-viral genetic modification system with the potential to deliver therapeutic payloads to various cell types to address a broad range of therapeutic applications.
Along with other non-viral gene therapy platforms, TcBuster has been extensively studied as a tool for intracellular gene transfer for cell and gene therapy. TcBuster can revolutionize your biological research and can provide you with the tool you need to make useful cell lines, produce proteins, vaccines and much more.
TcBuster addresses your challenges with:
- the high cost of virus-based genetic modification
- the inaccessibility of virus-based modification reagents
- the cargo size constraints of virus-based systems
Enhance Your Gene Transfer with TcBuster
TcBuster is a transposon-based technology used to deliver your gene-of-interest safely and randomly into a host’s genome. Watch how TcBuster can help you achieve your genome engineering goals.
This new article in Cell & Gene Therapy Insights discusses the transposon-based TcBuster platform and its competitive advantages in cell and gene therapy.
- Directed evolution of hyperactive TcBuster
- TcBuster in cell therapies
- Advantages and applications of TcBuster
- Q&A with the authors
Read the Article at Bio-Techne
Overcome Limits of Electroporation
Our Cutting edge non-viral vector transgene insertion platform harnesses DNA transposons for stable gene transfer into any cell type. TcBuster overcomes the three major technical challenges of other transposon systems.
- Insertion efficiency – Greater than 40% insertion efficiency for stable integration in T-cells.
- DNA toxicity – Proprietary techniques reduce effects of DNA toxicity.
- Random integration of enzyme DNA into host genome – Random delivery of transposase as mRNA or protein.
Transposons have demonstrated a safe gene delivery system insertion profile while maintaining high-efficiency gene transfer. DNA transposons enable rapid generation of transgenic mammalian cells with limited off-target effects and stable, reliable gene expression.
TcBuster Transposon Delivery in Activated T Cells
TcBuster Transposon Delivery in Resting Cells
Bio-Techne believes in the power of partnerships. We have joined with Fresenius Kabi and Wilson Wolf to bring you ScaleReady™, lowering the barriers to entry into the immune cell therapy space for all sizes and stages of manufacturing programs. ScaleReady brings cell and gene therapies to life by offering a significant reduction of complexity and cost while consistently providing superior repeatability and cell quality.
The ScaleReady product portfolio supports scalable immune cell expansion, delivering true platform, process, and product continuity for your immune cell programs. When paired with the Lovo® and Cue® functionally-closed-system automated cell processing systems, Bio-Techne reagents and the G-Rex® Bioreactor enable high throughput parallel processing of cell therapies within a small footprint.
Partner with ScaleReady for TcBuster applications in immune cell therapy. For other applications of TcBuster, contact a gene engineering expert at Bio-Techne.
“We have been utilizing R&D Systems for the last two years to take on our most challenging gene engineering projects. They provide the most up-to-date engineering tools, strategies, and techniques to ensure the quickest turn-around of the final cells. The R&D Systems team really has some of the brightest and most tenacious scientists that treat our project as if it was their own research.”
Senior Scientist, Fortune 25 Pharmaceutical Company, West Coast
Related Information
New T Cell-Based Therapies eBook (at bio-techne.com)
Discovery Solutions for Cell and Gene Therapy (at bio-techne.com)
Cell and Gene Therapy Solutions (at bio-techne.com)
GMP Proteins (at bio-techne.com)
GMP Small Molecules (at bio-techne.com)
Excellerate™ Media for Immune Cell Culture (at bio-techne.com)
Fluorokines™ Fluorescent-Labeled Recombinant Proteins
Simple Plex (at bio-techne.com)
MFI™ (at bio-techne.com)
GMP Capabilities (at bio-techne.com)